Johnson & Johnson Advances AFib Care with OMNY-AF Trial and Innovative OMNYPULSE Platform
Johnson & Johnson’s New Data Highlights Promising Neuropsychiatry Advances
TREMFYA® Achieves Remarkable Outcomes in Treating Crohn’s Disease and Ulcerative Colitis
Johnson & Johnson MedTech Unveils VOLTâ„¢ Plating System for Enhanced Fracture Care
Multiple Myeloma Treatment Advances: CEPHEUS Study Highlights Promising Results for D-VRd Regimen
DARZALEX® Receives Positive CHMP Opinion for Newly Diagnosed Myeloma
Johnson & Johnson’s Subsidiary Files for Bankruptcy to Resolve Ovarian Cancer Talc Claims
Lung Cancer Breakthrough: FDA Approves Rybrevant for EGFR Mutated Non-Small Cell Lung Cancer
RYBREVANT® Plus Chemotherapy Shows Positive Survival Trend in EGFR-Mutated Lung Cancer
RYBREVANT® Plus Chemotherapy Shows 49% Response in Metastatic Colorectal Cancer
Shockwave Medical Expands Peripheral IVL Portfolio with E8 Catheter
TAR-200 Plus Cetrelimab Doubles Response in Muscle-Invasive Bladder Cancer